ERBB2 and ovarian carcinoma: Our laboratory previously characterized trastuzumab uptake in nude mice bearing HER2+ xenografts of the human ovarian cancer cell line SKOV3 following a 1 mg/kg dose (Abuqayyas and Balthasar, 2012), and this data was used to evaluate model prediction accuracy.